{"id":"NCT00464672","sponsor":"Novartis","briefTitle":"Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old","officialTitle":"A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2007-07","completion":"2007-12","firstPosted":"2007-04-24","resultsPosted":"2010-05-05","lastUpdate":"2015-10-01"},"enrollment":1893,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Influenza virus vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator influenza vaccine","otherNames":[]}],"arms":[{"label":"Influenza virus vaccine","type":"EXPERIMENTAL"},{"label":"Comparator influenza vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide countries, according to the US FDA Draft Guidance for Industry \"Clinical data needed to support the licensure of trivalent inactivated influenza vaccine\", issued in March 2006, and to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine already licensed in US. The purpose of the control arm is primarily to provide a comparative assessment for safety, not immunogenicity or effectiveness.","primaryOutcome":{"measure":"Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age","timeFrame":"21 days after vaccination","effectByArm":[{"arm":"Influenza Virus Vaccine (A/H1N1)","deltaMin":93,"sd":null},{"arm":"Influenza Virus Vaccine (A/H3N2)","deltaMin":96,"sd":null},{"arm":"Influenza Virus Vaccine (Strain B)","deltaMin":91,"sd":null},{"arm":"Comparator Influenza Vaccine (A/H1N1)","deltaMin":99,"sd":null},{"arm":"Comparator Influenza Vaccine (A/H3N2)","deltaMin":100,"sd":null},{"arm":"Comparator Influenza Vaccine (Strain B)","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Argentina"]},"refs":{"pmids":["22691101"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":460},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Fatigue"]}}